Vantage logo

Bristol needs to get fresh

Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.

Vantage logo

Biotech catalysts on the horizon

The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.